- Home
- BDRX vs OGEN Comparison
BDRX vs OGEN Comparison
Compare BDRX & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- OGEN
- Stock Information
- Founded
- BDRX 2000
- OGEN 1996
- Country
- BDRX United Kingdom
- OGEN United States
- Employees
- BDRX N/A
- OGEN N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- OGEN Health Care
- Exchange
- BDRX Nasdaq
- OGEN Nasdaq
- Market Cap
- BDRX 2.8M
- OGEN 4.5M
- IPO Year
- BDRX N/A
- OGEN N/A
- Fundamental
- Price
- BDRX $5.98
- OGEN $0.34
- Analyst Decision
- BDRX Strong Buy
- OGEN
- Analyst Count
- BDRX 1
- OGEN 0
- Target Price
- BDRX $200.00
- OGEN N/A
- AVG Volume (30 Days)
- BDRX 455.7K
- OGEN 392.1K
- Earning Date
- BDRX 10-29-2024
- OGEN 11-07-2024
- Dividend Yield
- BDRX N/A
- OGEN N/A
- EPS Growth
- BDRX N/A
- OGEN N/A
- EPS
- BDRX N/A
- OGEN N/A
- Revenue
- BDRX $104,895.00
- OGEN $7,466.00
- Revenue This Year
- BDRX N/A
- OGEN N/A
- Revenue Next Year
- BDRX N/A
- OGEN N/A
- P/E Ratio
- BDRX N/A
- OGEN N/A
- Revenue Growth
- BDRX N/A
- OGEN N/A
- 52 Week Low
- BDRX $4.71
- OGEN $0.29
- 52 Week High
- BDRX $220.25
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- BDRX 42.77
- OGEN 36.96
- Support Level
- BDRX $5.50
- OGEN $0.29
- Resistance Level
- BDRX $10.89
- OGEN $0.35
- Average True Range (ATR)
- BDRX 1.13
- OGEN 0.04
- MACD
- BDRX 0.31
- OGEN 0.02
- Stochastic Oscillator
- BDRX 20.55
- OGEN 31.19
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.